2476. Impact of the Vaccination Strategy on Varicella Burden Disease in Argentina
Session: Poster Abstract Session: Vaccines for Herpes Zoster Virus
Saturday, October 6, 2018
Room: S Poster Hall
Posters
  • Varicela IDWeek 2018...pdf (622.5 kB)
  • Background:

    Varicella (VZV) is one of the most frequent exanthematic diseases in childhood. In Argentina, around 150,000-180,000 total cases per year are registered; however, underreport exists and some 400,000 cases are estimated to occur annually. Varicella vaccine (VV) was included in the national immunization schedule (NIS) in 2015, with a 1-dose schedule administered at 15 months of age. The information provided by epidemiological surveillance is essential to evaluate the impact of public health decisions.

    Our objective is to describe and to compare the epidemiological situation of VZV infections in Argentina in two periods: pre (2010-2014) and post (2016-2017) vaccine introduction in NIS.

    Methods:

    Descriptive study. We compared cases and incidence rates (R) of VZV per 100,000 population (global and disaggregated by age) reported to the National Health Surveillance System; in pre (Pre-VV) and post-vaccination (Post-VV) periods. Data analysis of 2015 was excluded since it was considered a transition year.

    Results:

    Vaccination coverage for 2015 was 44.7%; 74.4% in 2016 and 75.5% in 2017. 728,392 cases of VZV were notified (R = 362,1) in Pre-VV period and 176,995 cases in Post-VV (R = 220,6), with a global incidence rate reduction of 39% (IC95% =38,9-39,6 p <0.001). Both 12-24 months of age and 2-4 years old groups (Pre-VV R 2,253 and Post-VV R 1,077; Pre-VV R 2,400 and Post-VV R 1,165, respectively) showed the greatest reductions in incidence rates (-52.2% [IC95% 51.3-53] p <0.001 and -51.4% [IC95% 51-52] p <0.001). Besides, age groups not affected by vaccination (<1 year, 5-9 years and 10-14 years) presented minor but significant reductions (-49.1% [95% CI 44.5-53.4] p <0.001; -23% [IC95% 22.4-23.6] p <0.001, and -17% [IC95% 16.4-19] p <0.001 respectively).

    Conclusion:

    Three years after the implementation of VZV vaccination strategy, a significant incidence rates reduction is recorded, especially in children <5 years old, despite suboptimal coverage. Improving vaccination coverage will likely reflect a greater impact on the burden of disease.

    Silvina Neyro, MD, Carolina Rancaño, MD, Maria Iglesias, MD, Nathalia Katz, MD, María Del Valle Juarez, MD, Marina Pasinovich, MD, Martin Saralegui, BEd and Cristián Biscayart, MD, Dirección De Control De Enfermedades Inmunoprevenibles, Ministerio de Salud de la Nación, Ciudad Autónoma de Buenos Aires, Argentina

    Disclosures:

    S. Neyro, None

    C. Rancaño, None

    M. Iglesias, None

    N. Katz, None

    M. D. V. Juarez, None

    M. Pasinovich, None

    M. Saralegui, None

    C. Biscayart, None

    Previous Abstract | Next Abstract >>

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.